Abstract
Alemtuzumab has been proposed as a therapeutic agent in myeloma. CD52 was detected on plasma cells in 46/106 patients but levels were 30-fold lower than on alemtuzumab-responsive cells (n=138) and 8-fold lower than on alemtuzumab-resistant cells (n=57). The data suggest that myeloma plasma cells are unlikely to be depleted by alemtuzumab in most patients.
Publication types
-
Comparative Study
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alemtuzumab
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / therapeutic use*
-
Antigens, CD / biosynthesis*
-
Antigens, CD / genetics*
-
Antigens, Neoplasm / biosynthesis*
-
Antigens, Neoplasm / genetics*
-
CD52 Antigen
-
Gene Expression Regulation, Neoplastic / immunology
-
Glycoproteins / biosynthesis*
-
Glycoproteins / genetics*
-
Humans
-
Multiple Myeloma / genetics
-
Multiple Myeloma / metabolism*
-
Multiple Myeloma / therapy*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antigens, CD
-
Antigens, Neoplasm
-
CD52 Antigen
-
CD52 protein, human
-
Glycoproteins
-
Alemtuzumab